Skip to main content
Premium Trial:

Request an Annual Quote

Battered by Weak Pharma Market, Qiagen Slashes Sales Outlook; Shares Plummet

Click here for an updated version of this article.


NEW YORK, July 3 - Qiagen today said a weak second quarter caused it to slash its sales targets for the year by 13 percent to around $300 million, and warned it may record just $350 million in sales next year.

The news triggered a flash-flood sell-off of Qiagen stock on the Nasdaq exchange, where shares fell nearly 38 percent, or $3.80, to $6.22, in mid-morning trade. The lowest the shares have traded over the past year before today's announcement was $10.01.

Qiagen complained in a statement that a marked slowdown in R&D spending by US drug companies battered its instrumentation and synthetic nucleic-acid business, and added that the straights were dire enough to affect sales and earnings for the rest of this year and 2003.

"What happened in the second quarter is that pharmaceutical revenues in the US, instead of growing rapidly, were actually flat or declined," Peer Schatz, Qiagen's chief financial officer, told Dow Jones Newswires. "This has got nothing to do with our products. We think there is a short-term contraction in pharmaceutical budgets."


He also told Dow Jones that the second-quarter developments will not alter the company's strategy.

Qiagen said it expects to make $.05 per share in the current second quarter, down from $.09 per share, and expects to make $.05 and $.06 per share for the third and fourth quarters, respectively. Qiagen's original projection was to earn $.11 per share for both periods.

Though next year should see a 48-percent jump in per-share earnings, to $.34, Qiagen said, that would still be significantly lower than the $.45 average forecasted by analysts up until this morning's statement.

Stressing a bright spot, Qiagen said that though instrumentation accounts for just 11 percent of its total worldwide sales, and that some 35 percent of its sales   are from the pharmaceutical industry, fully half of its total revenues come from academia, which remains a strong customer base.


Click here for more information.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.